Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Antiviral immunity backfires: Pathogenic effects of type I interferon signaling in fetal development.

Casazza RL, Lazear HM.

Sci Immunol. 2018 Jan 5;3(19). pii: eaar3446. doi: 10.1126/sciimmunol.aar3446. Review.

PMID:
29305463
2.

Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection.

Premkumar L, Collins M, Graham S, Liou GA, Lopez CA, Jadi R, Balmaseda A, Brackbill JA, Dietze R, Camacho E, De Silva AD, Giuberti C, Dos Reis HL, Singh T, Heimsath H, Weiskopf D, Sette A, Osorio JE, Permar SR, Miley MJ, Lazear HM, Harris E, de Silva AM.

J Clin Microbiol. 2018 Feb 22;56(3). pii: e01504-17. doi: 10.1128/JCM.01504-17. Print 2018 Mar.

PMID:
29263206
3.

Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection.

Collins MH, McGowan E, Jadi R, Young E, Lopez CA, Baric RS, Lazear HM, de Silva AM.

Emerg Infect Dis. 2017 May;23(5):773-781. doi: 10.3201/eid2305.161630.

4.

What to Expect When You're Expecting Zika.

Lazear HM.

Cell Host Microbe. 2017 Mar 8;21(3):305-308. doi: 10.1016/j.chom.2017.02.015.

5.

A Reverse Genetics Platform That Spans the Zika Virus Family Tree.

Widman DG, Young E, Yount BL, Plante KS, Gallichotte EN, Carbaugh DL, Peck KM, Plante J, Swanstrom J, Heise MT, Lazear HM, Baric RS.

MBio. 2017 Mar 7;8(2). pii: e02014-16. doi: 10.1128/mBio.02014-16.

6.

Regional astrocyte IFN signaling restricts pathogenesis during neurotropic viral infection.

Daniels BP, Jujjavarapu H, Durrant DM, Williams JL, Green RR, White JP, Lazear HM, Gale M Jr, Diamond MS, Klein RS.

J Clin Invest. 2017 Mar 1;127(3):843-856. doi: 10.1172/JCI88720. Epub 2017 Jan 30.

7.

MAVS Is Essential for Primary CD4+ T Cell Immunity but Not for Recall T Cell Responses following an Attenuated West Nile Virus Infection.

Luo H, Winkelmann E, Xie G, Fang R, Peng BH, Li L, Lazear HM, Paessler S, Diamond MS, Gale M Jr, Barrett AD, Wang T.

J Virol. 2017 Feb 28;91(6). pii: e02097-16. doi: 10.1128/JVI.02097-16. Print 2017 Mar 15.

8.

Zika virus - reigniting the TORCH.

Coyne CB, Lazear HM.

Nat Rev Microbiol. 2016 Nov;14(11):707-715. doi: 10.1038/nrmicro.2016.125. Epub 2016 Aug 30. Review.

PMID:
27573577
9.

A Mouse Model of Zika Virus Pathogenesis.

Lazear HM, Govero J, Smith AM, Platt DJ, Fernandez E, Miner JJ, Diamond MS.

Cell Host Microbe. 2016 May 11;19(5):720-30. doi: 10.1016/j.chom.2016.03.010. Epub 2016 Apr 5.

10.

The Emerging Zika Virus Epidemic in the Americas: Research Priorities.

Lazear HM, Stringer EM, de Silva AM.

JAMA. 2016 May 10;315(18):1945-6. doi: 10.1001/jama.2016.2899. No abstract available.

PMID:
26963564
11.

Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere.

Lazear HM, Diamond MS.

J Virol. 2016 Apr 29;90(10):4864-4875. doi: 10.1128/JVI.00252-16. Print 2016 May 15. Review.

12.

The TAM receptor Mertk protects against neuroinvasive viral infection by maintaining blood-brain barrier integrity.

Miner JJ, Daniels BP, Shrestha B, Proenca-Modena JL, Lew ED, Lazear HM, Gorman MJ, Lemke G, Klein RS, Diamond MS.

Nat Med. 2015 Dec;21(12):1464-72. doi: 10.1038/nm.3974. Epub 2015 Nov 2.

13.

Interferon-Regulatory Factor 5-Dependent Signaling Restricts Orthobunyavirus Dissemination to the Central Nervous System.

Proenca-Modena JL, Hyde JL, Sesti-Costa R, Lucas T, Pinto AK, Richner JM, Gorman MJ, Lazear HM, Diamond MS.

J Virol. 2015 Oct 14;90(1):189-205. doi: 10.1128/JVI.02276-15. Print 2016 Jan 1.

14.

Interferon-λ: Immune Functions at Barrier Surfaces and Beyond.

Lazear HM, Nice TJ, Diamond MS.

Immunity. 2015 Jul 21;43(1):15-28. doi: 10.1016/j.immuni.2015.07.001. Review.

15.

Selective Blockade of Interferon-α and -β Reveals Their Non-Redundant Functions in a Mouse Model of West Nile Virus Infection.

Sheehan KC, Lazear HM, Diamond MS, Schreiber RD.

PLoS One. 2015 May 26;10(5):e0128636. doi: 10.1371/journal.pone.0128636. eCollection 2015.

16.

Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier.

Lazear HM, Daniels BP, Pinto AK, Huang AC, Vick SC, Doyle SE, Gale M Jr, Klein RS, Diamond MS.

Sci Transl Med. 2015 Apr 22;7(284):284ra59. doi: 10.1126/scitranslmed.aaa4304. Erratum in: Sci Transl Med. 2015 May 27;7(289):289er5.

17.

Oropouche virus infection and pathogenesis are restricted by MAVS, IRF-3, IRF-7, and type I interferon signaling pathways in nonmyeloid cells.

Proenca-Modena JL, Sesti-Costa R, Pinto AK, Richner JM, Lazear HM, Lucas T, Hyde JL, Diamond MS.

J Virol. 2015 May;89(9):4720-37. doi: 10.1128/JVI.00077-15. Epub 2015 Feb 25.

18.

New insights into innate immune restriction of West Nile virus infection.

Lazear HM, Diamond MS.

Curr Opin Virol. 2015 Apr;11:1-6. doi: 10.1016/j.coviro.2014.12.001. Epub 2014 Dec 31. Review.

19.

Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity.

Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, Diamond MS, Virgin HW.

Science. 2015 Jan 16;347(6219):269-73. doi: 10.1126/science.1258100. Epub 2014 Nov 27.

20.

Interferon regulatory factor 5-dependent immune responses in the draining lymph node protect against West Nile virus infection.

Thackray LB, Shrestha B, Richner JM, Miner JJ, Pinto AK, Lazear HM, Gale M Jr, Diamond MS.

J Virol. 2014 Oct;88(19):11007-21. doi: 10.1128/JVI.01545-14. Epub 2014 Jul 16.

21.

Propagation, quantification, detection, and storage of West Nile virus.

Brien JD, Lazear HM, Diamond MS.

Curr Protoc Microbiol. 2013 Nov 5;31:15D.3.1-15D.3.18. doi: 10.1002/9780471729259.mc15d03s31.

PMID:
24510289
22.

K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5.

Harikumar KB, Yester JW, Surace MJ, Oyeniran C, Price MM, Huang WC, Hait NC, Allegood JC, Yamada A, Kong X, Lazear HM, Bhardwaj R, Takabe K, Diamond MS, Luo C, Milstien S, Spiegel S, Kordula T.

Nat Immunol. 2014 Mar;15(3):231-8. doi: 10.1038/ni.2810. Epub 2014 Jan 26.

23.

Pattern recognition receptor MDA5 modulates CD8+ T cell-dependent clearance of West Nile virus from the central nervous system.

Lazear HM, Pinto AK, Ramos HJ, Vick SC, Shrestha B, Suthar MS, Gale M Jr, Diamond MS.

J Virol. 2013 Nov;87(21):11401-15. doi: 10.1128/JVI.01403-13. Epub 2013 Aug 21.

24.

IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling.

Lazear HM, Lancaster A, Wilkins C, Suthar MS, Huang A, Vick SC, Clepper L, Thackray L, Brassil MM, Virgin HW, Nikolich-Zugich J, Moses AV, Gale M Jr, Früh K, Diamond MS.

PLoS Pathog. 2013 Jan;9(1):e1003118. doi: 10.1371/journal.ppat.1003118. Epub 2013 Jan 3. Erratum in: PLoS Pathog. 2013 May;9(5). :10.1371/annotation/4de7ddfd-52df-4f87-8ca4-d48afe646ca8.

25.
26.

Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication.

Thackray LB, Duan E, Lazear HM, Kambal A, Schreiber RD, Diamond MS, Virgin HW.

J Virol. 2012 Dec;86(24):13515-23. doi: 10.1128/JVI.01824-12. Epub 2012 Oct 3.

27.

West Nile virus noncoding subgenomic RNA contributes to viral evasion of the type I interferon-mediated antiviral response.

Schuessler A, Funk A, Lazear HM, Cooper DA, Torres S, Daffis S, Jha BK, Kumagai Y, Takeuchi O, Hertzog P, Silverman R, Akira S, Barton DJ, Diamond MS, Khromykh AA.

J Virol. 2012 May;86(10):5708-18. doi: 10.1128/JVI.00207-12. Epub 2012 Feb 29.

28.

Interferon regulatory factor-1 (IRF-1) shapes both innate and CD8(+) T cell immune responses against West Nile virus infection.

Brien JD, Daffis S, Lazear HM, Cho H, Suthar MS, Gale M Jr, Diamond MS.

PLoS Pathog. 2011 Sep;7(9):e1002230. doi: 10.1371/journal.ppat.1002230. Epub 2011 Sep 1.

29.

Beta interferon controls West Nile virus infection and pathogenesis in mice.

Lazear HM, Pinto AK, Vogt MR, Gale M Jr, Diamond MS.

J Virol. 2011 Jul;85(14):7186-94. doi: 10.1128/JVI.00396-11. Epub 2011 May 4.

30.

The naturally attenuated Kunjin strain of West Nile virus shows enhanced sensitivity to the host type I interferon response.

Daffis S, Lazear HM, Liu WJ, Audsley M, Engle M, Khromykh AA, Diamond MS.

J Virol. 2011 Jun;85(11):5664-8. doi: 10.1128/JVI.00232-11. Epub 2011 Mar 16.

31.

The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo.

Lubinski JM, Lazear HM, Awasthi S, Wang F, Friedman HM.

J Virol. 2011 Apr;85(7):3239-49. doi: 10.1128/JVI.02509-10. Epub 2011 Jan 12.

Supplemental Content

Loading ...
Support Center